ChiCTR2600123773 版本V1.1 版本创建时间2026/04/29 16:54:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123773 

最近更新日期:

Date of Last Refreshed on:

2026-04-29 16:54:42 

注册时间:

Date of Registration:

2026-04-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于病灶大小分层的主动性内镜切除策略在小型胃固有肌层黏膜下病变中的应用:帽吸切除术与常规内镜全层切除术的单中心回顾性队列研究

Public title:

Proactive Endoscopic Resection for Small Gastric Submucosal Tumors by Lesion Size: A Retrospective Cohort Study of Cap-Assisted Resection vs. Conventional Endoscopic Full-Thickness Resection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于病灶大小分层的主动性内镜切除策略在小型胃固有肌层黏膜下病变中的应用:帽吸切除术与常规内镜全层切除术的单中心回顾性队列研究

Scientific title:

Proactive Endoscopic Resection for Small Gastric Submucosal Tumors by Lesion Size: A Retrospective Cohort Study of Cap-Assisted Resection vs. Conventional Endoscopic Full-Thickness Resection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吕聪 

研究负责人:

吕聪 

Applicant:

Lü Cong 

Study leader:

Lü Cong 

申请注册联系人电话:

Applicant telephone:

+86 18296742533

研究负责人电话:

Study leader's
telephone:

+86 10 15642378

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lvconghl@163.com

研究负责人电子邮件:

Study leader's E-mail:

lvcong@mail.gzsrmyy.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国江西省赣州市章贡区梅关大道16号

研究负责人通讯地址:

中国江西省赣州市章贡区梅关大道16号

Applicant address:

16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi, China

Study leader's address:

16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

赣州市人民医院

Applicant's institution:

Ganzhou People's Hospital

研究负责人所在单位:

赣州市人民医院

Affiliation of the Leader:

Ganzhou People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

PJB2026-110-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

赣州市人民医院临床科研伦理分委员会

Name of the ethic committee:

Research Ethics Sub-Committee of Ganzhou People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-09 00:00:00

伦理委员会联系人:

刘文群

Contact Name of the ethic committee:

Liu Wenqun

伦理委员会联系地址:

中国江西省赣州市章贡区梅关大道16号

Contact Address of the ethic committee:

16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 797 5889157

伦理委员会联系人邮箱:

Contact email of the ethic committee:

408488245@qq.com

研究实施负责(组长)单位:

赣州市人民医院

Primary sponsor:

Ganzhou People's Hospital

研究实施负责(组长)单位地址:

中国江西省赣州市章贡区梅关大道16号

Primary sponsor's address:

16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江西

市(区县):

Country:

China

Province:

Jiangxi

City:

单位(医院):

赣州市人民医院

具体地址:

中国江西省赣州市章贡区梅关大道16号

Institution
hospital:

Ganzhou People's Hospital

Address:

16 Meiguan Avenue, Zhanggong District, Ganzhou, Jiangxi, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

固有肌层黏膜下病变  

Target disease:

Muscularis propria subepithelial lesion

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1. 主要目的 (1) 描述本中心小型胃固有肌层黏膜下病变接受主动性内镜切除后的技术成功率、R0切除率、病理诊断收益及短期随访结局。 (2) 评估主动性内镜切除路径在真实世界中获得明确病理诊断及短期局部控制的可行性。 2. 次要目的 (1) 分析CASL与C-EFTR在真实世界中的适用边界、围手术期指标及资源消耗差异。 (2) 探索与C-EFTR选择相关的临床因素,并评估随访成熟度与缺失模式。 (3) 为本院后续规范化管理小型胃固有肌层黏膜下病变提供依据,并为学术论文发表形成合规伦理基础。  

Objectives of Study:

Primary Objectives (1) To describe the technical success rate, R0 resection rate, pathological diagnostic yield, and short-term follow-up outcomes of proactive endoscopic resection for small gastric submucosal tumors arising from the muscularis propria in our center. (2) To evaluate the feasibility of achieving a definitive pathological diagnosis and short-term local control using proactive endoscopic resection pathways in a real-world setting. Secondary Objectives (1) To analyze the applicability boundaries, perioperative parameters, and resource consumption differences between cap-assisted snare resection (CASL) and conventional endoscopic full-thickness resection (C-EFTR) in a real-world setting. (2) To explore clinical factors associated with the selection of C-EFTR, and to assess follow-up maturity and missing data patterns. (3) To provide evidence for standardized management of small gastric muscularis propria submucosal tumors in our hospital, and to establish a compliant ethical foundation for future academic publications.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

2023年8月4日至2025年12月23日期间就诊于赣州市人民医院并完成相关内镜治疗; 1.年龄>=18岁,性别不限; 2.胃部病变,术前EUS提示起源于固有肌层; 3.最大记录直径<=20 mm; 4.接受CASL或C-EFTR作为常规临床治疗; 5.关键基线、围手术期及病理资料可从原始病历中获取;

Inclusion criteria

1.Patients who visited the People's Hospital of Ganzhou and underwent the relevant endoscopic treatment between August 4, 2023, and December 23, 2025; 2.Aged >=18 years, male or female; 3.Gastric lesions with preoperative EUS suggesting origin from the muscularis propria; 4.Maximum recorded diameter <=20 mm; 5.Underwent CASL or C-EFTR as routine clinical treatment; 6.Key baseline, perioperative, and pathological data available from original medical records;

排除标准:

1.非胃部病变;
2.非固有肌层来源病变或来源层次无法确认;
3.接受其他内镜技术或直接外科手术而非CASL或C-EFTR治疗;
4.重复记录或同一病灶重复入组;
5.关键围手术期资料或病理结果缺失,无法支持主要终点判断;
6.经研究者判定存在明显数据完整性或伦理合规问题,不适合纳入分析;

Exclusion criteria:

1.Non-gastric lesions;
2.Lesions not originating from the muscularis propria or with an unidentifiable layer of origin;
3.Received other endoscopic techniques or direct surgical procedures instead of CASL or C-EFTR;
4.Duplicate records or repeated enrollment of the same lesion;
5.Missing key perioperative data or pathological results that preclude assessment of the primary endpoints;
6.Cases judged by the investigator to have significant data integrity or ethical compliance issues, making them unsuitable for inclusion in the analysis;

研究实施时间:

Study execute time:

From 2026-04-30 00:00:00 To 2026-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-01 00:00:00 To 2026-05-30 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

120

Group:

Observation Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江西 

市(区县):

 

Country:

China

Province:

Jiangxi

City:

单位(医院):

赣州市人民医院 

单位级别:

三甲 

Institution
hospital:

Ganzhou People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

技术成功率

指标类型:

主要指标

Outcome:

Technical success rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

切缘状态及 R0 切除率

指标类型:

主要指标

Outcome:

Margin status and R0 resection rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病理诊断收益

指标类型:

主要指标

Outcome:

Pathological diagnostic yield

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床意义延迟不良事件

指标类型:

主要指标

Outcome:

Clinically meaningful delayed adverse events

Type:

Primary indicator

测量时间点:

30 天内

测量方法:

Measure time point of outcome:

Within 30 days

Measure method:

指标中文名:

短期随访结局

指标类型:

主要指标

Outcome:

Short-term follow-up outcomes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围手术期指标(术中全层开放/主动穿孔、鼻胃管留置、手术时间、术后住院天数、总住院天数)

指标类型:

次要指标

Outcome:

Perioperative outcomes (full-thickness opening/active perforation during surgery, nasogastric tube placement, operative duration, postoperative hospital stay, total hospital stay)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

资源消耗指标(耗材费用和总住院费用)

指标类型:

次要指标

Outcome:

Resource utilization metrics (instrumentation costs and total hospitalization costs)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

随访可得率、随访时长及随访成熟度

指标类型:

次要指标

Outcome:

Follow-up availability rate, follow-up duration, and follow-up maturity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病灶大小、病灶部位、年份等因素与术式选择及围手术期结果之间的关联

指标类型:

次要指标

Outcome:

Association between lesion size, lesion location, year, and surgical approach selection and perioperative outcomes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age NA years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录、电子病例管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Medical record,Electronic medical record (EMR) management system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-29 16:54:26